Skip to main content

Table 1 Clinical and sociodemographic patient characteristics

From: Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?

 

n = 135

Frequency (%)

Age

Mean (SD)

65.3a (8.5a)

Range

47-85

Marital status

Single

8 (5.9%)

Partnership, marriage

70 (51.9%)

Divorced, separated

20 (14.8%)

Widowed

18 (13.3%)

Employment status

Full time

7 (5.2%)

Part time

9 (6.7%)

Unemployed

3 (2.2%)

Homemaker

18 (13.3%)

Retired

76 (56.3%)

Other

3 (2.2%)

Diagnosis

in situ

13 (9.6%)

invasive

121 (89.6%)

Duration of adjuvant endocrine therapy (months)

Mean (SD)

29.5 (17.3)

Range

2.5-70.8

Primary surgical treatment

Breast conserving surgery

87 (64.9)

Mastectomy

47 (35.1)

Chemotherapy

yes

27 (20%)

Radiotherapy

yes

98 (72.6%)

BMI

Mean (SD)

25.2 (4.3)

Median

25.2

range

19.5-43.7

Estradiol

≤12

119 (88.1%)

>12

16 (11.9%)

Median

12 ng/L

Minimum-Maximum

<12 -69 ng/L

LH

Mean (SD)

26.5 (10.2)

Median

25.6 U/L

Minimum-Maximum

0.1-62.10 U/L

range

62 U/L

FSH

Mean (SD)

83.3 (28.0) U/L

Median

81.4 U/L

Minimum-Maximum

26.40-188 U/L

range

161.6 U/L

SHBG

Mean (SD)

50.3 (20.2) nmol/l

Median

45.5 nmol/l

Minimum-Maximum

12.3-116 nmol/l

range

103.7 nmol/l